United States Department of Justice | Tuesday, September 5, 2017 | FOR IMMEDIATE RELEASE | Novo Nordisk Agrees to Pay $58 Million for Failure to Comply with FDA-Mandated Risk Program | Blogger: Holding Big Pharma accountable!!. That's a joke, right!! 💨 Sometimes pharma companies bend the rules. And increasingly, they're getting caught. How do they solve it? By settlement with the U.S. Attorney's office. A slap on the wrist💥Novo Nordisk increased reported operating profit by 8% in the first six months of 2017💥Sales increased by 4% in Danish kroner and by 3% in local currencies to DKK 57.1 billion. Sales of Tresiba® increased by 155% to DKK 3.7 billion (149% in local currencies) Sales of Victoza® increased by 21% to DKK 11.5 billion (18% in local currencies) Sales of Saxenda® increased by 98% to DKK 1.2 billion (90% in local currencies) Sales in North America Operations increased by 5% (2% in local currencies) Sales in International Operations increased by 4% (5% in local currencies).. In short, Novo Nordisk U.S. Holdings Inc., which is a subsidiary of Novo Nordisk A/S of Denmark, the world's largest producer of insulin, trying to sell Victoza in America, ignoring high risk factors and symptoms, linked to dangerous side effects, including pancreatitis and thyroid cancer 💣 BLACK BOX WARNINGS: Risk of thyroid C-cell tumors 💣In detail, the injectable Type 2 diabetes drug Victoza works by stimulating insulin production. It belongs to a class of drugs called GLP-1 mimetics. Studies link Victoza to pancreatitis, thyroid cancer and pancreatic cancer... |
